FDA批准Inlexzo, 一种新的膀胱癌治疗 显示80%以上的患者反应率。 FDA approves Inlexzo, a new bladder cancer treatment showing over 80% patient response rate.

林业发展局批准了Inlexzo,这是针对成年人的一种新治疗,即卡介苗反应不灵敏的非肌肉侵入性膀胱癌,现场有癌瘤,无论有无毛虫肿瘤。 The FDA has approved Inlexzo, a new treatment for adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Inlexzo 是第一个膀胱内药物释放系统，可将药物吉西他滨直接延长局部递送至膀胱。 Inlexzo is the first intravesical drug-releasing system that provides extended local delivery of the drug gemcitabine directly into the bladder. 根据临床研究数据,80%以上的病人获得了完全的治疗,一半以上的病人至少将这一治疗维持了一年。 Based on clinical study data, over 80% of patients achieved a complete response, with more than half maintaining this response for at least a year. Johnson & Johnson获得了批准。 Approval was granted to Johnson & Johnson.